Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (21-30 of 118) with videos related to

Pageof 12
Sort By:
Biometrical Journal. Biometrische Zeitschrift|July 19, 2006
The likelihood as statistical evidence in multiple comparisons in clinical trials: no free lunchEdward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Reply to H. Uno et al and B. Huang et alBoris Freidlin, Edward L Korn
Journal of the National Cancer Institute|February 26, 2016
RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2024
Efficiency of Biomarker-Driven Clinical Trial DesignsBoris Freidlin, Edward L Korn
Controlled Clinical Trials|August 6, 2002
A comment on futility monitoringBoris Freidlin, Edward L Korn
Lancet (London, England)|January 16, 2004
Erythropoietin to treat anaemia in patients with head and neck cancerBoris Freidlin, Edward L Korn
Journal of the National Cancer Institute|September 28, 2017
Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?Boris Freidlin, Edward L Korn
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?Edward L Korn, Boris Freidlin
Biometrical Journal. Biometrische Zeitschrift|July 12, 2007
A posterior taleEdward L Korn, Boris Freidlin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2013
Borrowing information across subgroups in phase II trials: is it useful?Boris Freidlin, Edward L Korn
Pageof 12

Showing results (21-30 of 118) with videos related to

Sort By:
Pageof 12
Biometrical Journal. Biometrische Zeitschrift|July 19, 2006
The likelihood as statistical evidence in multiple comparisons in clinical trials: no free lunchEdward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Reply to H. Uno et al and B. Huang et alBoris Freidlin, Edward L Korn
Journal of the National Cancer Institute|February 26, 2016
RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalBoris Freidlin, Edward L Korn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2024
Efficiency of Biomarker-Driven Clinical Trial DesignsBoris Freidlin, Edward L Korn
Controlled Clinical Trials|August 6, 2002
A comment on futility monitoringBoris Freidlin, Edward L Korn
Lancet (London, England)|January 16, 2004
Erythropoietin to treat anaemia in patients with head and neck cancerBoris Freidlin, Edward L Korn
Journal of the National Cancer Institute|September 28, 2017
Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?Boris Freidlin, Edward L Korn
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2018
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?Edward L Korn, Boris Freidlin
Biometrical Journal. Biometrische Zeitschrift|July 12, 2007
A posterior taleEdward L Korn, Boris Freidlin
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2013
Borrowing information across subgroups in phase II trials: is it useful?Boris Freidlin, Edward L Korn
Pageof 12